DDInter1576 DDInter899
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Regorafenib {u} (Compound) resembles {v} (Compound) Sorafenib
Regorafenib {u} (Compound) binds {v} (Gene) CYP2C9
Regorafenib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Regorafenib {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Regorafenib (Compound) resembles Sorafenib (Compound)
Regorafenib (Compound) binds CYP2C9 (Gene)
Regorafenib (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Regorafenib (Compound) causes Myocardial infarction (Side Effect)
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Regorafenib may lead to a major life threatening interaction when taken with Fondaparinux
Regorafenib may lead to a major life threatening interaction when taken with Venetoclax